Show Notes
Are your legs painful to touch and resistant to weight loss despite your best efforts? Dr. Ellen Derrick, a vascular surgeon and lipedema specialist, reveals the truth about this misunderstood condition affecting 20% of women worldwide. Lipedema isn't obesity - it's a fat cell disorder where tissue responds abnormally to inflammation, creating painful, swollen areas that don't respond to traditional weight loss methods. She explains the connection between lipedema and venous insufficiency, why patients are often dismissed by doctors, and the emerging treatments offering hope. KEY TAKEAWAYS Lipedema affects 20% of the female population but is routinely misdiagnosed as obesity The condition involves abnormal fat cell response to inflammation, creating painful tissue that resists weight loss 86% of lipedema patients also have venous insufficiency, creating a perfect storm of symptoms Ankle cuffs, knee pouches, and saddlebags are classic physical signs that patients often notice from puberty GLP-1 medications like tirzepatide may help reduce inflammation and tissue tenderness Lipedema reduction surgery exists but lacks insurance billing codes, making access challenging A formal medical recognition campaign is underway to establish diagnostic codes by 2026-2027 NOTABLE QUOTE "The medical community really has done an outstanding job, in a way, gaslighting these patients. These patients have been aware that something is different about their body and their legs since puberty." — Dr. Ellen Derrick GUEST BIO Dr. Ellen Derrick is a Seattle-based board-certified vascular and general surgeon with over 20 years of clinical experience and a Master of Public Health from the University of Washington. She founded Boxbar Vascular, specializing in lipedema and related metabolic conditions, and serves on the board of the Lipedema Society working toward formal medical recognition of the condition. Links & Resources Podcast Home: fatsciencepodcast.com Cooper Center for Metabolism: coopermetabolic.com Resources from Dr. Cooper: coopermetabolic.com/resources Join Our Community: patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
More from Fat Science
Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress. Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses. The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves. Key Takeaways Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms. Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses. Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential. Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake. Resources Mentioned Diabesity Foundations Course Cooper Center for Metabolism Diabesity Institute Connect with Us Podcast Home:fatsciencepodcast.com Cooper Center for Metabolism:coopermetabolic.com Diabesity Institute: diabesityinstitute.org Resources from Dr. Cooper:coopermetabolic.com/resources Join Our Community:patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations. Produced by: Podcast Impact Studio https://podcastimpactstudio.com
What do new drug reports really mean for your treatment? Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues. KEY TAKEAWAYS Understanding the difference between efficacy estimand and treatment policy estimand.
Can metabolic dysfunction be the cause of anxiety?
What's the back-to-school metabolism shift all about?